Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Non Operating Income: 2019-2024

Historic Non Operating Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to $16.1 million.

  • Foghorn Therapeutics' Non Operating Income fell 43.93% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 3.39%. This contributed to the annual value of $16.1 million for FY2024, which is 17.20% up from last year.
  • According to the latest figures from FY2024, Foghorn Therapeutics' Non Operating Income is $16.1 million, which was up 17.20% from $13.7 million recorded in FY2023.
  • Foghorn Therapeutics' 5-year Non Operating Income high stood at $16.1 million for FY2024, and its period low was -$269,000 during FY2020.
  • Moreover, its 3-year median value for Non Operating Income was $13.7 million (2023), whereas its average is $12.7 million.
  • In the last 5 years, Foghorn Therapeutics' Non Operating Income slumped by 511.36% in 2020 and then skyrocketed by 1,027.14% in 2021.
  • Foghorn Therapeutics' Non Operating Income (Yearly) stood at -$269,000 in 2020, then soared by 1,027.14% to $2.5 million in 2021, then surged by 230.99% to $8.3 million in 2022, then spiked by 66.03% to $13.7 million in 2023, then rose by 17.20% to $16.1 million in 2024.